Abstract: A method for training a machine learning system, including: based on at least one image dataset representing at least one portion of the hollow structure, calculating a signed distance field of each portion and calculating at least one geometrical parameter of each portion; generating a deployed in-use representation of the device by computing contact forces between the device and each portion based on the signed distance field and by applying these contact forces to a geometrical representation of the device; and training the machine learning system with each calculated geometrical parameter as an input and the corresponding deployed in-use representation as an associated target output, the obtained trained machine learning system being configured to receive as input at least one geometrical parameter and provide as output the deployed in-use representation of the device.

Abstract: The invention relates to immunogenic peptides encoded by an open reading frame (ORF) encoded by at least part of the genome of a coronavirus in the opposite sense to positive sense RNA capable of translation. The invention also relates to polynucleotides encoding such peptide, the use of such peptides and polynucleotides for the treatment and prevention of viral infection, and complexes comprising the peptides of the invention.

Abstract: The device for regulating the pressure of a sanitary hot water circuit and, consequently, a flow rate of hot water exiting at least one outlet forming part of a sanitary hot water distribution installation having at least one source of hot water supplying a pump (2) that pressurizes the hot water, at least one circuit of small-bore pipes (5.2) conveying the pressurized hot water to at least one outlet (41), and a regulating system is characterized in that the regulating system has a pressure reducer (90) positioned upstream of each small-bore hot water circuit, and in that the device has means for determining the pressure in each small-bore pipe (5.2) at the outlet or outlets and for transmitting this pressure information to the corresponding pressure reducer (90) at the outlet or outlets. The invention also relates to the method implementing this device.

Abstract: The invention relates to vaccine compositions comprising peptides encoded by an open reading frame (ORF) encoded by at least part of the genome of a ssRNA virus in the opposite sense to positive sense RNA capable of translation, and the use of such compositions for the treatment and prevention of viral infection.

Abstract: The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.

Abstract: Disclosed are combinations of a H3 antagonist and an antidepressant, which exhibit a synergistic wake promoting activity.

Abstract: A computer-implemented method, a computer program, a storage medium, and a system for reconstructing a geometry of the mitral valve of a subject as open and as closed, based on a sequence of echography images acquired from the subject. The sequence of echography images represents the mitral valve apparatus during at least one heart cycle.

Abstract: The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.

Abstract: This application relates to amatoxin analogs in which the trans-4-substituent on the proline residue of the amatoxin is an R group other than a hydroxy, constructs comprising such amatoxin analogs coupled to a linker and conjugates comprising such amatoxin analog-linker constructs conjugated to a target moiety. The application also relates to uses of such amatoxin analogs, for example, in treatment of cancer.

Abstract: The invention described herein is based in part on the discovery of a protein/peptide crosslink, which introduces fluorescent properties, and which has been applied to synthesize analogues of melanocortin and amanitin as choice peptides to be explored in the context of isoindole peptides. Without limitation, it is expected that those trained in the art of peptide synthesis and stapling would appreciate the consequences of this invention such that other peptides of varied length can be similarly constrained by isoindole staples as featured herein.

Abstract: The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.

Abstract: The aspects herein relate to the field of fall prevention systems, and more specifically to fall arrest systems for storage bins and more particularly to grain bins or silos. In one aspect, a fall prevention system for a ladder may have an anchor plate coupled to a roof. In another aspect, the fall prevention system for the ladder may have an anchor bar coupled to at least a portion of the ladder. A rope is coupled at one end to the anchor plate or bar and at the other end to at least one rung of the ladder using a fastener. A rope grab is slidably coupled to the rope between the anchor plate or bar and the fastener.

Abstract: A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be —CO2H, —SO2H, —SO3H, —PO2H, or —PO3H2, for example. R2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.

Abstract: A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be —CO2H, —SO2H, —SO3H, —PO2H, or —PO3H2, for example. R2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.

Abstract: The invention described herein is based in part on the discovery of a protein/peptide crosslink, which introduces fluorescent properties, and which has been applied to synthesize analogues of melanocortin and amanitin as choice peptides to be explored in the context of isoindole peptides. Without limitation, it is expected that those trained in the art of peptide synthesis and stapling would appreciate the consequences of this invention such that other peptides of varied length can be similarly constrained by isoindole staples as featured herein.

Abstract: The invention described herein is based in part on the discovery of a protein/peptide crosslink, which introduces fluorescent properties, and which has been applied to synthesize analogues of melanocortin and amanitin as choice peptides to be explored in the context of isoindole peptides. Without limitation, it is expected that those trained in the art of peptide synthesis and stapling would appreciate the consequences of this invention such that other peptides of varied length can be similarly constrained by isoindole staples as featured herein.

Abstract: This application relates to compounds of Formula (I): [targeting peptide]-N(R1)—X1(R2)L1-[linker]-RXn1 (I). The targeting peptide is cyclo[L-Phe-L-Tyr-L-Lys(iPr)-D-Arg-L-2-Nal-Gly-D-Glu]-L-Lys(iPr). R1 is H or methyl. X1 is an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms. R2 is C(O)OH or C(O)NH2. L1 is a linkage (thiolether, amide, maleimide-thiol, triazole). The linker has a net negative charge at physiological pH and is a linear or branched chain of 1-10 units of X2L2 and/or X2(L2)2, wherein: each X2 is, independently, an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms; and each L2 is a linkage. The linker optionally further comprises an albumin binder bonded to an L2. Each RX is a radiolabelling group linked through a separate L2, selected from: a metal chelator; a prosthetic group containing trifluoroborate (BF3); or a prosthetic group containing a silicon-fluorine-acceptor moiety.

Abstract: Disclosed are combinations of a H3 antagonist and an antidepressant, which exhibit a synergistic wake promoting activity.

Abstract: A compound or molecular complex. The compound or molecular complex comprises: a metal chelator configured for chelation with a radioactive isotope or a non-radioactive isotope; and a trifluoroborate (BF3)-containing moiety configured for 19F/18F exchange or a precursor thereof; and optionally a cell-targeting domain.

Abstract: Fluoridated organofluoroborates comprising at least one 18F atom and precursors thereto, for use in PET scanning.